Skip to main content
. Author manuscript; available in PMC: 2019 Sep 13.
Published in final edited form as: Nature. 2019 Mar 13;567(7749):521–524. doi: 10.1038/s41586-019-1012-y

Figure 1: Efficacy of MEK1/2 inhibition with cobimetinib across molecular subtypes of histiocytoses.

Figure 1:

(a) Waterfall plot of the maximum change in tumor metabolism according to standardized uptake values (SUVs) measured by positron emission tomography (PET). Colors of bars indicate genomic alteration present. Notations above bars indicate specific mutation. One patient (dagger) died due to underlying disease prior to first response evaluation. The lower dotted lines represent cut-off for partial response. (b) Swimmer plot of outcomes in all 18 patients. (c) PET-Defined progression-free survival (n=18).